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Summary 
Vector-borne viral infections represent a pressing public health challenge, particularly in the tropics. Field 
releases of mosquitoes carrying bacterial symbionts that reduce vector competence are ongoing in Kuala 
Lumpur, Malaysia. Early results show that wAlbB Wolbachia can persist in mosquitoes in urban settings 
and decrease dengue fever incidence in humans.  
Main text 
The control of vector-borne diseases is a challenging task, as proven by their increasing morbidity burden 
worldwide. Traditional means of control typically provide only short-term benefits and have a range of 
other issues. The use of insecticides, for example, requires a very high coverage of target areas and selects 
for resistance that degrades ongoing effectiveness. Urban settings make the control of mosquito breeding 
sites, like water-filled trash or containers, logistically difficult. Other interventions, such as the use of bed 
nets, is largely ineffective for mosquito species that bite during daytime, including Aedes aegypti, the 
vector of dengue, Zika and chikungunya viruses. The laborious nature of control, combined with global 
warming that is expanding the range of the mosquito, help explain the 30-fold increase in the number of 
dengue fever cases in the last 50 years [1]. The World Health Organization has hence declared dengue 
“the most important mosquito-borne viral disease in the world” [1]. 
Wolbachia, a widespread maternally-inherited bacterial symbiont of insects, has emerged as a viable tool 
to control vector-borne diseases. Insects harbouring this microbe have lower viral loads than their 
uninfected counterparts, a trait known as virus blocking [2,3]. Aedes aegypti mosquitoes (Figure 1) are 
naturally uninfected with Wolbachia, but have been artificially transinfected with multiple Wolbachia 
strains that form stably inherited infections. These infections render the insects less susceptible to 
contracting and transmitting arboviruses [4]. 
Since these advances, a few teams have focused on leveraging the antiviral properties of Wolbachia for 
human disease prevention. WHO has recommended carefully planned pilot Wolbachia deployments 
under field conditions to test for efficacy with respect to reducing human disease incidence [5]. Field 
interventions include rearing of Wolbachia-infected mosquitos in specialised facilities and release into the 
environment in dengue-affected areas. Wolbachia is then passed from female mosquitos to their offspring 
every generation, and can establish in wild populations due cytoplasmic incompatibility – the mechanism 
facilitating its own spread. Once established, Wolbachia blocks replication of arboviruses in mosquitoes, 
which become unable to spread disease-causing viruses to humans [6].  
The first pilot releases of Wolbachia-infected Aedes aegypti to block dengue virus spread were pioneered 
by the largest Wolbachia-based initiative, The World Mosquito Program [6]. First deployed in 2011, the 
releases are now ongoing in 12 countries, and all use the same Wolbachia strain – wMel derived from the 
fruit fly, Drosophila melanogaster [7]. Despite an intense effort over the last eight years, epidemiological 
data showing decrease in dengue cases among humans are limited to the single area in Australia [8]. This 
area is historically characterised by episodic outbreaks of the disease caused by imported virus, that have 
now been quelled by Wolbachia release [8].  
Dengue control in endemic tropical areas presents a greater challenge, as well as a more pressing issue 
for human suffering and economic losses. Now, Nazni, Hoffmann et al. have shown that the wAlbB 
Wolbachia strain can be successfully deployed for dengue control in urban, dengue endemic areas of 
Malaysia [9]. Wolbachia-infected mosquitoes were released in a number of carefully selected, differently 
structured and populated sites. Similar, intervention-free control sites were selected and monitored in 
parallel. The results show that Wolbachia can establish at high frequencies in most local mosquito 
populations in these complex urban settings. More importantly, Wolbachia deployment translates to a 5-
65% decrease in the number of human dengue cases, with the exact reduction depending on the site. As 
the authors note, these numbers likely underestimate the benefit of release, as daily human movement 
between residential release sites and untreated areas enables import of the disease. Precise 
quantification of the effect size awaits data on the rate of intra-household transmission events, which 
provide a more focussed measure of the local benefits of the control measure [10]. 
The evident success of this small-scale release has inspired trust from the Malaysian Ministry of Health, 
which supports extension of this strategy into a larger number of locations. As such, despite being a 
relatively small observational study, this release programme will be important for turning Wolbachia-
based control from a promising strategy into a validated tool. Although large scale, randomised field trials 
are required to prove the effectiveness of Wolbachia-based biocontrol, smaller releases are invaluable for 
planning and optimization of the these more powerful and expensive designs [10].  
The work presented by Nazni, Hoffmann and colleagues is foundational for the larger scale trial designs 
for several reasons. The releases in variable urban environments facilitate generalisation of the results, as 
the number of people living in large cities is on the rise globally [11]. Additionally, the study demonstrates 
that the release of Aedes aegypti eggs (Figure 2) (rather than a combination of eggs and adults [6]) can be 
successful in the field, reducing intervention costs and implementation times. The most important 
innovation, however, is the use of a wAlbB Wolbachia strain, which has not previously been deployed in 
open releases. The wAlbB strain of Wolbachia originates from Aedes albopictus, a close relative of Aedes 
aegypti, and has a number of characteristics that can make it favourable in comparison with the more 
commonly applied wMel. wAlbB-host interactions are more robust at high environmental temperatures, 
maintaining higher Wolbachia loads, high maternal transmission and stronger cytoplasmic incompatibility 
than the wMel-mosquito symbioses [12,13]. All these properties are crucial for the long-term stability of 
the intervention and its associated disease prevention. Efficient maternal transmission and cytoplasmic 
incompatibility ensure high numbers of dengue resistant mosquitoes in the wild, while high Wolbachia 
densities are correlated with strong antiviral protection [14,15]. Robustness in the face of elevated 
temperatures is key, as vector-borne diseases are most prevalent in hot climates. In areas where wMel 
fails to establish or its effectiveness drops over time, the use of wAlbB or release of double infected wMel-
wAlbB mosquitoes [16] may be necessary. 
This successful use of Wolbachia in dengue prevention, albeit on a small scale, raises some important 
questions. Will Wolbachia in general, and wAlbB in particular, prove effective against dengue in the long 
term? As the mechanism of Wolbachia-mediated pathogen blocking remains elusive, it is difficult to 
predict how Wolbachia, mosquitoes and viruses will evolve in the post-release landscape. Although RNA 
viruses, which include dengue, Zika and chikungunya, are expected to evolve very fast, one set of recent 
laboratory-based experiments was unable to select for dengue virus variants resistant to Wolbachia 
inhibition [17]. The evolutionary stability of the antiviral phenotype has recently been confirmed in wMel-
infected Aedes aegypti, where artificial selection for reduced virus blocking reduced mosquito fitness [18]. 
Thus, there are reasons to be hopeful, at least in the short term, that the blocking phenotype will remain 
robust [18]. Finally, the stability of wMel Wolbachia phenotypes in field-established Wolbachia-infected 
Aedes mosquitoes in Australia has been confirmed, by testing their fitness and pathogen blocking 
properties [19,20]. Similar data remain to be gathered for the wAlbB Wolbachia strain. In all field sites 
however, the growing interaction between mosquito and virus genetic diversity and Wolbachia-mediated 
blocking will need to be monitored. 
To what extent will Wolbachia reduce the burden of vector-borne disease? Wolbachia-conferred 
protection is broad in nature, working against many double-stranded positive-sense RNA viruses and 
some other pathogens [2,4]. As the implementation of Wolbachia spreads, monitoring of dengue fever 
and other diseases, including Zika and chikungunya, will provide an answer. Although more work is 
required to confirm the degree of protection, the results so far hold a promise for a future with reduced 
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Figure 1. Aedes aegypti mosquito. The image shows a blood-fed female Aedes aegypti, vector of dengue, 




Figure 2. Mosquito eggs. The image shows Aedes aegypti eggs. Photo credit: Steve Morton.  
 
